Streetbeat News

Regulatory

THCX

The cannabis industry is facing a downturn due to regulatory challenges, market saturation, and shifting investor sentiment, despite its long-term growth potential. THCX may be mentioned as a relevant asset.

Portfolio Pulse from

December 08, 2024 | 7:15 pm

AGIO

Agios Pharmaceuticals announced positive results from its Phase 3 ENERGIZE-T study of Mitapivat, achieving primary and key secondary endpoints in adult patients with transfusion-dependent alpha- or beta-thalassemia. The company also provided a regulatory update on Mitapivat.

Portfolio Pulse from

December 08, 2024 | 6:00 pm

ADBE

AVGO

COST

GME

ORCL

The Federal Reserve is focusing on inflation with an upcoming CPI report before the final FOMC meeting of 2024. Key earnings reports this week include Oracle, GameStop, Adobe, Broadcom, and Costco.

Portfolio Pulse from

December 08, 2024 | 5:45 pm

APLT

Levi & Korsinsky has initiated an investigation into Applied Therapeutics, Inc. (APLT) for potential federal securities law violations. This follows the FDA's issuance of a Complete Response Letter for APLT's drug govorestat.

Portfolio Pulse from

December 08, 2024 | 1:30 pm

PARA

Skydance Media is nearing regulatory approval for an $8 billion merger with Paramount Global. The deal, which has faced challenges, could soon be finalized.

Portfolio Pulse from

December 08, 2024 | 4:30 am

ADPT

Adaptive Biotechnologies presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® MRD testing in influencing treatment decisions for blood cancers such as MCL, CLL, MM, and ALL.

Portfolio Pulse from

December 07, 2024 | 11:45 pm

UNH

The recent fatal shooting of a UnitedHealth Group executive has raised concerns about potential regulatory changes in the health insurance industry, which could impact investor expectations of a deregulatory environment.

Portfolio Pulse from

December 07, 2024 | 12:30 pm

UNH

The recent UnitedHealth incident has brought attention to the health insurance sector. If Congress does not take action, healthcare plans may become more expensive, potentially increasing the uninsured rate and premiums.

Portfolio Pulse from

December 07, 2024 | 11:30 am

CAPR

Capricor Therapeutics is progressing with deramiocel, a cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Phase 2 trials showed significant improvements, but prior commercialization deals may limit upside.

Portfolio Pulse from

December 07, 2024 | 10:30 am

FMCC

FNMA

Fannie Mae and Freddie Mac, major mortgage backers, are facing challenges due to increasing climate risks such as floods and wildfires. Addressing these risks involves significant trade-offs.

Portfolio Pulse from

December 07, 2024 | 10:30 am